Some additional cytogenetic aberrations in patients treated with Imatinib (STI571)

被引：0
|
作者：
Salamanczuk, Z. [1 ]
Jakobczyk, M. [1 ]
Sacha, T. [1 ]
Skotnicki, A. B. [1 ]
机构：
[1] Jagiellonian Univ, Dept Haematol, PL-31007 Krakow, Poland
来源：
CHROMOSOME RESEARCH | 2005年 / 13卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [1] Pharmacology of imatinib (STI571)
    Buchdunger, E
    O'Reilly, T
    Wood, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S28 - S36
  • [2] Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)
    Dressman, MA
    Malinowski, R
    McLean, LA
    Gathmann, I
    Capdeville, R
    Hensley, M
    Polymeropoulos, MH
    CLINICAL CANCER RESEARCH, 2004, 10 (07) : 2265 - 2271
  • [3] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [4] Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC)
    Hasserjian, RP
    Chase, A
    Dhar, S
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    LABORATORY INVESTIGATION, 2002, 82 (01) : 244A - 244A
  • [5] Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC)
    Hasserjian, RP
    Chase, A
    Dhar, S
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    MODERN PATHOLOGY, 2002, 15 (01) : 244A - 244A
  • [6] Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571).
    O'Dwyer, M
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Fong, D
    Hsieh, YC
    Mori, M
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 137A - 138A
  • [7] RNAi meets imatinib mesylate (STI571)
    Eder, M
    Scherr, M
    BLOOD, 2003, 102 (06) : 1942 - 1942
  • [8] Follicular mucinosis associated with imatinib (STI571)
    Yanagi, T
    Sawamura, D
    Shimizu, H
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (06) : 1276 - 1278
  • [9] Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib mesylate (STI571).
    Mauro, MJ
    O'Dwyer, ME
    Kurilik, G
    Blasdel, C
    Farnsworth, M
    Fong, D
    Hsieh, YC
    Mori, M
    Ford, JM
    Druker, BJ
    BLOOD, 2001, 98 (11) : 139A - 139A
  • [10] The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations
    Marin, D
    Marktel, S
    Bua, M
    Armstrong, L
    Goldman, JM
    Apperley, JF
    Olavarria, E
    HAEMATOLOGICA, 2002, 87 (09) : 979 - 988
12345